ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, has announced positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)....
Read More
2 Minutes
